Open an account

RadNet

RDNT · NASDAQ

$69.65+$0.38 (+0.55%)TodayMarket closed ·
Prev close $69.27

About RDNT

RadNet, Inc. provides freestanding, fixed-site outpatient diagnostic imaging services in the United States. The company is headquartered in Los Angeles, California and currently employs 8,844 full-time employees. The company went IPO on 2001-12-12. The firm has a network of 407 owned and/or operated outpatient imaging centers. Its Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Its services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. Its Digital Health segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. The company provides radiology information technology and artificial intelligence (AI) solutions marketed under the DeepHealth brand and teleradiology professional services. The company is also a provider of AI-powered breast health solutions.

Employees
8,844
Headquarters
Los Angeles, California
Listed
Dec 12, 2001
Sector
Health Care
Industry
Health Care Providers & Services
Website
radnet.com

RDNT key statistics

Market cap
5.48B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
562.99K
Volume
326.29K
Open price
$69.92
High today
$71.06
Low today
$69.03
52 Week high
$85.84
52 Week low
$50.82

RadNet (RDNT) at a glance

As of Oct 20, 2026, RadNet (RDNT) shares are priced at $69.65, giving the company a market cap of 5.48B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $69.03 and $71.06. The current price is 0.9% above the day's low and 2.0% below its high.

Volume so far is 326.29K shares, below the average of 562.99K shares a day.

Over the past year RadNet has ranged from $50.82 to $85.84, and now sits 54% of the way up that range.

RadNet met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported $0.29 per share against an estimate of $0.2069.

The average analyst price target is $96.52, 38.6% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 4 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 10 analystsAvg $96.52
Low
$79.79
Now
$69.65
High
$110.25

RDNT earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 35.2% on average.

  1. Q3 FY24: reported $0.18 per share against an estimate of $0.1489
  2. Q4 FY24: reported $0.22 per share against an estimate of $0.2076
  3. Q1 FY25: reported -$0.35 per share against an estimate of -$0.1338
  4. Q2 FY25: reported $0.31 per share against an estimate of $0.1598
  5. Q3 FY25: reported $0.20 per share against an estimate of $0.2279
  6. Q4 FY25: reported $0.24 per share against an estimate of $0.2084
  7. Q1 FY26: reported -$0.28 per share against an estimate of -$0.2186
  8. Q2 FY26: reported $0.29 per share against an estimate of $0.2069

RDNT news

  • Press releaseGlobe Newswire

    RadNet, Inc. to Present at the Jefferies Healthcare Services and Technology Conference on September 15, 2026

  • Press releaseGlobe Newswire

    RadNet Reports Second Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA(1) and Revises Upwards 2026 Financial Guidance Ranges

  • Press releasePRNewswire

    Cardiac AI Diagnostics Stack Validation Wins Across Regulatory and Commercial Fronts

  • Press releaseGlobe Newswire

    RadNet Reports Record First Quarter Financial Results and Revises Upwards 2026 Imaging Center Financial Guidance Ranges for Revenue, Adjusted EBITDA and Free Cash Flow

  • Press releaseBusiness Wire

    GE HealthCare expands mammography collaboration with RadNet's DeepHealth subsidiary to extend global access to DeepHealth's AI-powered breast cancer screening solutions

  • Press releasePRNewswire

    Hospital Networks Turn to AI-Enhanced Cardiac Imaging to Cut Costs and Improve Outcomes

  • Press releaseGlobe Newswire

    RadNet Reports Fourth Quarter 2025 Results, Including Record Revenue and Adjusted EBITDA⁽¹⁾ and Releases 2026 Financial Guidance

  • Press releasePRNewswire

    AI Medical Imaging Revolution: Software-Native Tech Disrupts $45B Market

Similar companies

Companies in the same industry as RadNet

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.